Nesic, Marijana
Sønderkær, Mads
Brøndum, Rasmus Froberg
El-Galaly, Tarec Christoffer
Pedersen, Inge Søkilde
Bøgsted, Martin
Dybkær, Karen
Article History
Received: 8 February 2021
Accepted: 7 July 2021
First Online: 18 July 2021
Declarations
:
: This study was carried out in accordance with national health ethics guidelines and all the experimental protocols for involving humans were under the ProSeq (approval jr. N-20160089) research protocol approved by the Health Ethics Committee of the North Denmark Region or the RetroSeq (approval jr. 1706295 NVK) research protocol approved by the the Danish National Committee on Health Research. The study consists of two cohorts of patients from the Department of Hematology, Aalborg University Hospital, Denmark where patients with relapse of DLBCL were enrolled in the ProSeq protocol giving written informed consent in accordance with the Declaration of Helsinki and archival biopsies from patients with diagnostic DLBCL were collected in agreement with the RetroSeq protocol allowing exemption from the Declaration of Helsinki requirement of informed consent according to sections 3 to 5 in the Danish Act on Research Ethics Review of Health Research Projects. Informed consent for diagnostic DLBCL patients was waived by the Danish National Committee on Health Research, as this notifiable research project did not involve any health risks and, under the given conditions, could not otherwise put a strain on the trial subject. In addition, it would be impossible or disproportionately difficult to obtain informed consent or proxy consent, respectively, because of the use of archival samples and because several patients have died since collection.
: Not applicable.
: No conflicts to disclose.